1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Glioblastoma Research Program (GRMRP) is a grant initiative led by The Mark Foundation for Cancer Research and The Sontag Foundation, in coalition with other philanthropies and brain cancer leaders, that funds innovative, cross-disciplinary research aimed at improving the diagnosis and treatment of glioblastoma.
The program emerged from the "No Stone Unturned" workshop held in Chicago in November 2024, which convened global leaders in neuro-oncology to identify the most critical barriers to progress in GBM. Eligible recipients are scientists and research teams pursuing bold therapeutic ideas and cross-institutional collaborations in glioblastoma.
Get alerted about grants like this
Get emailed when new opportunities from “The Mark Foundation for Cancer Research and The Sontag Foundation (in partnership with other organizations)” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Partnering to Advance Glioblastoma Research | The Mark Foundation for Cancer Research The Mark Foundation for Cancer Research The Mark Foundation for Cancer Research Partnering to Advance Glioblastoma Research Changing the Future of Glioblastoma Care Glioblastoma (GBM) is the most aggressive and common primary malignant brain tumor in adults, and for decades, it has remained fundamentally incurable.
With a median survival of less than 18 months and long-term survival rates below 10%, a therapeutic breakthrough is desperately needed. In recognition of this critical challenge, The Mark Foundation for Cancer Research and The Sontag Foundation are leading a coalition of philanthropies and brain cancer leaders to fund research aimed at overcoming the obstacles to effective diagnosis and treatment.
By enabling bold, cross-disciplinary science, the coalition aims to transform the future of glioblastoma care and offer new hope to patients and families. The No Stone Unturned Workshop To overcome the many obstacles to progress in developing effective glioblastoma therapies, The Mark Foundation and Sontag Foundation co-hosted a landmark scientific workshop in Chicago in November 2024.
Titled No Stone Unturned: Relentless Pursuit of a Cure for Glioblastoma , the workshop was organized by William Kaelin Jr., MD (Dana-Farber Cancer Institute), Sheila Singh, MD, PhD (King’s College London), and Timothy Cloughesy, MD (UCLA), who brought together global leaders in neuro-oncology and translational science.
Workshop participants discussed new approaches to identification, validation, and drug discovery for new targets, sparking new collaborations and laying the groundwork for our funding strategy. Learn more about the workshop. In 2026, partner organizations Fondation Anne et Claude Berda , the National Brain Tumor Society , the Southeastern Brain Tumor Foundation , and the Uncle Kory Foundation joined the coalition.
2026 Awarded Research Projects In February 2026, the coalition announced that the following five researchers and teams have been awarded grant funding to pursue research aimed at changing the current glioblastoma treatment paradigm.
These grants were made possible in part by generous support from the families of Amiram Elwork and Rachael Elwork Wells, in whose memory this work is dedicated, honoring the lives of a father and daughter both lost to glioblastoma.
Aneuploidies as a Source of Therapeutic Targets in Glioblastoma Rameen Beroukhim, MD, PhD, Broad Institute of MIT and Harvard, Dana-Farber Cancer Institute William Kaelin Jr., MD; and Keith Ligon, MD, PhD , Dana-Farber Cancer Institute, Broad Institute of MIT and Harvard Daniel Schramek, PhD, Lunenfeld-Tanenbaum Research Institute Jason Moffat, PhD, The Hospital for Sick Children Antisense Oligonucleotides (ASOs) Targeting the Long Noncoding RNA as Novel Immunotherapeutic Agents in Glioblastoma E.
Antonio Chiocca, MD, PhD and Marco Mineo, PhD, Brigham and Women’s Hospital Targeting Platelet-Immune Cell Interactions for Next-Generation Glioblastoma Therapies Justin Lathia, PhD, Cleveland Clinic Identifying Drivers and Therapeutic Targets in IDH-Mutant and IDH-Wildtype Glioma Daniel Schramek, PhD, Lunenfeld-Tanenbaum Research Institute, and Daniel Wahl, MD, PhD, University of Michigan Spatial Profiling of CAR T Cell Interactions and Activation States in the Tumor Microenvironment of High-Grade Gliomas Peter Sorger, PhD, Harvard Medical School, and Christine Brown, PhD, City of Hope
According to the current listing, eligibility includes: Scientists pursuing innovative therapeutic ideas and collaborations for glioblastoma. Confirm the full requirements in the official notice before applying.
Glioblastoma Research Program (GRMRP) is funded by The Mark Foundation for Cancer Research and The Sontag Foundation (in partnership with other organizations). Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position. The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.
Smart Health and Biomedical Research in the Era of Artificial Intelligence and Advanced Data Science (SCH) is sponsored by National Science Foundation (NSF) & National Institutes of Health (NIH). This interagency program supports high-risk, high-reward advances in AI and data science for biomedical and public health research. Projects must cross disciplinary boundaries.
NSF X-Labs is unlike any NSF program in the agency's history: it runs on Other Transaction Authority, not a grant; it funds teams up to $1.5M in Phase 0 and as much as $50 million per year in Phase 1; and it demands an 8-page written proposal followed by an invitation-only oral defense in which NSF refuses to look at what you wrote. The Quantum Systems topic closes July 24, 2026. Here is what X-Labs actually is, why the structure signals a new NSF, and who is positioned to win a DARPA-style award from an agency that has never operated this way before.
Read articleThe Workforce Opportunity for Rural Communities Initiative returns for a seventh round with $49.2M for the Appalachian, Delta, and Northern Border regions — awards of $2M to $8M, an estimated 6 to 24 grants, and a July 23, 2026 deadline. Here is how the three-commission structure works, who is eligible, why WORC 7's shift toward large-scale regional sector partnerships changes who should apply, and how to build a proposal that survives the competition.
Read articleNSF 26-508 will deploy up to $224 million across 56 State/Territory AI Coordination Hubs over three to four years. Each hub gets $1M annually to build an AI Learning Resource Navigator, a state AI readiness plan, deployment support, capacity-building, and priority-sector coordination. The Letter of Intent is due June 16 and the full proposal July 16. Here is what the program is really buying, who is best positioned to win Round 1, and why the no-cost-share rule reshapes the partner landscape.
Read article